Takeda has exercised an option on partner Cour Pharmaceutical’s first-in-class lead product, after a positive Phase IIa study showed, for the first time, it was possible to induce specific immune tolerance to a foreign antigen in an autoimmune disease.

Acquiring Encycle Therapeutics brings Zealand Pharma a promising IBD asset and expands the breadth of its peptide discovery platform.

Buying two vaccines for rabies and tick-borne encephalitis complements the recently approved smallpox and monkeypox vaccine Jynneos. Now the Danish firm needs to start selling them.

Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.

Biogen surprised investors with news that it will file aducanumab with the FDA based on data from more patients treated at the highest dose than in the interim futility analysis that led to termination of two Phase III studies in March.

CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.

Farxiga, with a new indication to prevent hospitalization for heart failure in type 2 diabetes patients, is the first drug among the SGLT2 class to gain this indication outside of diabetics with renal disease.

New access agreement for samples from failed clinical trial to support identification of valuable new biomarkers, and possibly novel drugs, in highly challenging disorder.

CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.

Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.